期刊
SCIENCE
卷 359, 期 6382, 页码 1366-1370出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aar6918
关键词
-
资金
- Ligue Contre le Cancer (Equipe Labelisee)
- Agence Nationale de la Recherche (ANR)-Projets blancs
- ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases
- Association pour la Recherche sur le Cancer (ARC)
- Canceropole Ile-de-France
- Institut National du Cancer (INCa)
- Institut Universitaire de France
- Fondation pour la Recherche Medicale (FRM)
- European Commission (ArtForce)
- European Research Council (ERC)
- LeDucq Foundation
- LabEx Immuno-Oncology
- Site de Recherche Integree sur le Cancer (SIRIC) Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE)
- SIRIC Cancer Research and Personalized Medicine (CARPEM)
- Recherche Hospitalo-Universitaire-LUMIERE
- Seerave Foundation
- Institut Suisse de Recherche Experimentale sur le Cancer (ISREC) Foundation
- Swiss Foundation
- Paris Alliance of Cancer Research Institutes (PACRI)
- Natural Science Foundation of China (NSFC) [81722037, 81671630]
- China Ministry of Science and Technology (National key research and development program) [2017YFA0506200]
- Natural Science Foundation of Jiangsu Province [BK20170006, BK20160379]
- Chinese National Thousand Talents Program
- Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine [CAMS-I2M, 2016-I2M-1-005]
- Non-profit Central Research Institute Fund of CAMS [2016ZX310194, 2017NL31004, 2017RC31008]
- French Ministery/IHU Mediterranee Infections
- Team Science Award from the Melanoma Research Alliance [R35 CA210098]
- American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy
- University of Chicago Medicine Comprehensive Cancer Center
- Institutional Training Grant [T32 CA009594]
- Center for Research Informatics of The University of Chicago Biological Science Division
- Roche-Genentech
- BMS
- Merck
- Incyte
- Seattle Genetics
- Ono
The fine line between human health and disease can be driven by the interplay between host and microbial factors. This metagenome regulates cancer initiation, progression, and response to therapies. Besides the capacity of distinct microbial species to modulate the pharmacodynamics of chemotherapeutic drugs, symbiosis between epithelial barriers and their microbial ecosystems has a major impact on the local and distant immune system, markedly influencing clinical outcome in cancer patients. Efficacy of cancer immunotherapy with immune checkpoint antibodies can be diminished with administration of antibiotics, and superior efficacy is observed with the presence of specific gut microbes. Future strategies of precision medicine will likely rely on novel diagnostic and therapeutic tools with which to identify and correct defects in the microbiome that compromise therapeutic efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据